An observational study in Aortic Valve Stenosis, sponsored by Edwards Lifesciences. Completed at 11 sites in 6 countries. Per ClinicalTrials.gov, last updated 2024-11-04.
Sponsored by Edwards Lifesciences · Observational
This study will monitor device performance and safety of the Edwards CENTERA Transcatheter Heart Valve (THV) system in patients with severe, symptomatic aortic valve stenosis who are indicated for aortic valve replacement.
A prospective, international, single arm, multi-center post market clinical follow-up study.
1,006 studies on the registry are indexed under Aortic Valve Stenosis; 284 are open to participants now.
This study's enrollment of 87 is below the median of 200 across 431 observational studies indexed under Aortic Valve Stenosis.
Browse Aortic Valve Stenosis studies →Edwards Lifesciences is the lead sponsor of 128 studies on the registry; 18 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 33 (94%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adult patients with severe, symptomatic aortic valve stenosis who are indicated for aortic valve replacement.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Device: Transcatheter Aortic Valve Replacement (TAVR)
TAVR with the Edwards CENTERA THV System and accessories
All-Cause Mortality
All-cause mortality at 30 days
Time frame: 30 days
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.